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Mammalian artificial chromosomes (MACs) are non-integrating, autonomously 
replicating natural chromosome-based vectors that may carry a vast amount of genetic 
material, which in turn enable potentially prolonged, safe, and regulated therapeutic 
transgene expression, and render MACs as attractive genetic vectors for “gene 
replacement” or for controlling differentiation pathways in target cells. Satellite DNA-
based artificial chromosomes (SATACs) can be made by induced de novo chromosome 
formation in cells of different mammalian and plant species. These artificially generated 
accessory chromosomes are composed of predictable DNA sequences and they contain 
defined genetic information. SATACs have already passed a number of obstacles crucial 
to their further development as gene therapy vectors, including: large-scale purification; 
transfer of purified artificial chromosomes into different cells and embryos; generation of 
transgenic animals and germline transmission with purified SATACs; and the tissue-
specific expression of a therapeutic gene from an artificial chromosome in the milk of 
transgenic animals. SATACs could be used in cell therapy protocols. For these methods 
the most versatile target cell would be one that was pluripotent and self-renewing to 
address multiple disease target cell types, thus making multilineage stem cells, such as 
adult derived early progenitor cells and embryonic stem cells, as attractive universal host 
cells. 
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Background on Mammalian Artificial Chromosomes (MACs) 
Many groups worldwide have developed MACs and these technologies have been 
extensively reviewed (Ascenzioni et al. 1997; Basu and Willard 2005; Basu and Willard 
2006; Bridger 2004; Brown et al. 2000; Cooke 2001; Csonka 2011; Duncan and 
Hadlaczky 2007; Grimes et al. 2002; Grimes and Monaco 2005); Hadlaczky 2001; Larin 
and Mejía 2002; Lewis 2001; Lim and Farr 2004; Lipps et al. 2003; Macnab and 
Whitehouse 2009; Monaco and Moralli 2006; Ren et al. 2006; Kouprina et al. 2013; 
Kouprina et al. 2014). Four different strategies have been developed for the construction 
of artificial chromosomes (Irvine et al. 2005): (i) in the synthetic approach the artificial 
chromosome is assembled from chromosomal components (Basu et al. 2005a; Basu et al. 
2005b; Grimes et al. 2002; Harrington et al. 1997; Henning et al. 1999; Ikeno et al. 1998; 
Ikeno et al. 2009; Kaname et al. 2005; Kouprina et al. 2003; Nakashima et al. 2005; 
Suzuki et al. 2006), (ii) the ‘top down’ method applies the in vivo telomere-associated 
fragmentation of existing chromosomes (Au et al. 1999; Auriche et al. 2001; Carine et al. 
1986; Choo et al. 2001; Farr et al. 1995; Heller et al. 1996; Ishida et al. 2000; Katoh et al. 
2004; Mills et al. 1999; Shen et al. 2000; Voet et al. 2001; Wong et al. 2002)  , (iii) 
naturally occurring minichromosomes may be engineered to construct an artificial 
chromosome (Raimondi 2011), and (iv) de novo chromosome generation can be induced 
via targeted amplification of specific chromosomal segments (Carl 2004; Csonka et al. 
2000; Holló et al. 1996; Keresö et al. 1996; Lindenbaum et al. 2004; Praznovszky et al. 
1991; Tubak et al. 1991). To date, two technologies, the ‘top down’ and the induced de 
novo chromosome generation approaches have advanced to the point suitable for 
biotechnological applications. The artificial chromosome technology exploits the unique 
properties of artificial chromosomes as being engineered chromosomes with defined 
genetic contents, capable of functioning as non-integrating vectors with large carrying 
capacity and stability (Duncan and Hadlaczky 2007; Hadlaczky 2001; Katona et al. 
2011). The incorporation of different integrase and recombinase recognition sequences 
and integrase/recombinase enzyme genes into artificial chromosomes greatly improved 
the feasibility of integrating a transgene into the artificial chromosome (Duncan and 
Hadlaczky 2007; Katona et al. 2011; Kazuki and Oshimura 2011; Kouprina et al., 2013; 
Lindenbaum et al. 2004) . A MAC as a genetic vector should (1) possess large DNA 
payload capacity of 1 Mb or greater, (2) facilitate efficient gene(s) loading, (3) be capable 
of being transferred from one cell to another, and (4) enable stable, high-level transgene 
expression. Presently, there are three MAC technologies that have made the most 
progress in addressing these stringent requirements. First one is a class of truncated 
natural chromosomes (21ΔqHACs and 21ΔpqHACs), the second type is a de novo 
formed HAC (alphoidtetO-HAC) and the third is the satellite DNA-based artificial 
chromosomes (SATACs and ACEs). By systematically deleting euchromatin from 
natural chromosomes, truncation-derived MACs preserve functioning centromeres, 
telomeres, and DNA origins of replication, while minimizing potential gene dosage 
effects in host cells. Of particular interests are the two MACs that were generated by 
telomere-directed truncation of the distal q (“long”) arm of human acrocentric 
chromosome 21 generating 21ΔqHAC, and the subsequent truncation of the remaining 
distal p (“short”) arm generating 21ΔpqHAC (Katoh et al. 2004; Kazuki et al. 2011; 
Oshimura and Katoh 2008) . Of note, the remaining p arm of 21ΔqHAC is assumed to 
encode only a rDNA gene tandem array and pericentromeric heterochromatin and hence 
should be genetically “neutral.” Transgenes that have been efficiently loaded and 
expressed from these vectors include hypoxanthine guanine phosphoribosyl transferase 
(HPRT) (Ayabe et al. 2005; Grimes et al. 2001; Mejía et al., 2001) , enhanced green 
fluorescent protein (EGFP) (Yamada et al. 2006), antibody/cytokine receptor chimera 
(Kawahara et al. 2007), erythropoietin (EPO) (Kakeda et al. 2005), DNA-dependent 
protein kinase catalytic subunit (DNA-PKcs, critical for DNA repair) (Otsuki et al. 2005), 
proinsulin (Suda et al. 2006), human dystrophin (Messina et al. 2009), CD40L (Yamada 
et al. 2008), the human P53 (Kazuki et al. 2008), telomerase (Oshimura et al. 2008), 
genes for human growth hormone (HGH), polycystic kidney disease (PKD1) and beta-
globin (Basu et al. 2005a), CFTR (Auriche et al. 2002; Rocchi et al. 2010), GCH1 (Ikeno 
et al. 2002), factor IX (Breman et al. 2008),  NBS1 and VHL genes (Kim et al. 2011) and 
STAT3 (Ikeno et al. 2009). Several of these genes were loaded as genomic copies 
carrying all the necessary control regions for proper wild type gene expression. 
 
Overview of de novo formed stallite-based mammalian artificial chromosomes 
(SATAC) 
 
This review focuses on SATAC technology. The in vivo generation of SATACs is based 
upon the induction of large-scale amplification via integration of exogenous DNA into 
specific chromosomal regions (Holló et al. 1996). The short arm of acrocentric 
chromosomes, which contains tandemly repeated ribosomal RNA genes (rDNA) and 
different non-coding satellite DNA sequences, is an optimal chromosomal region for 
inducing de novo chromosome formation. Basically, any cultured mammalian cell line 
that contains rDNA region is suitable for the production of de novo formed SATACs. 
Figure 1 describes a step by step overview of SATAC formation. The possibility to use 
any mammalian cell line for SATAC formation is a major advantage of this technology 
over other de novo MAC systems. SATACs and ACEs primarily consist of 
heterochromatin and pericentromeric sequences, which are purported to be devoid of 
gene-coding sequences except for rDNA (Csonka et al. 2000; Hadlaczky et al. 1991; 
Hadlaczky 2001; Holló et al. 1996; Keresö et al. 1996; Lindenbaum et al. 2004; 
Praznovszky et al. 1991). There is no evidence in humans that amplification of these 
pericentromeric sequences is deleterious to an individual, as polymorphisms in the short 
arms of acrocentric chromosomes have been shown to consist of amplified 
pericentromeric heterochromatin and/or rDNA (Conte et al. 1997; Friedrich et al. 1996; 
Sands 1969; Sofuni et al. 1980; Stergianou et al. 1993; Trask et al. 1989A; Trask et al. 
1989B; Verma et al. 1977; Warburton et al., 1976) and have been inherited with no 
adverse effects (Bernstein et al. 1981; Cooper and Hirschhorn 1962; Schmid et al. 1994; 
Therkelsen 1964; Yoder et al. 1974). Furthermore, supernumerary chromosomes derived 
from amplified pericentromeric heterochromatin and/or rDNA sequences of acrocentric 
chromosomes have been shown to be stably inherited through 1-3 generations in humans 
without any deleterious effects of phenotypes (Adhvaryu et al. 1998; Blennow et al. 
1994; Brøndum-Nielsen and Mikkelsen 1995; Crolla et al. 1997; Hadlaczky et al. 2002; 
Howard-Peebles 1979; Mukerjee and Burdette 1966). Additionally, SATACs have been 
engineered with multiple (>50) site-specific recombination acceptor sites (attP) which 
enable the unidirectional loading of heterologous DNA (encoding an attB recombination 
donor site) via a mutant lambda integrase (Carl 2004; Lindenbaum et al. 2004) . The 
DNA recombination is unidirectional in mammalian cells, since the engineered integrase 
lacks the bacterial co-factors necessary for excision. The combination of the multiple attP 
sites on the ACEs and the unidirectional mutant integrase enables multiple loadings 
(during a single transfection) or sequential loadings (via multiple transfections) of 
transgenes (Kennard et al. 2009B; Lindenbaum et al. 2004). Transgenes that have been 
efficiently loaded and expressed from SATACs include enhanced green fluorescent 
protein (EGFP), red fluorescent protein (RFP), erythropoietin (EPO), monoclonal 
antibodies (MAbs) and therapeutic galactocerebrosidase transgenes to treat Krabbe 
disease in the Twitcher mice (Adriaansen et al. 2006; Carl 2004; Katona et al. 2008; 
Kennard et al. 2009A; Kennard et al. 2009B; Lindenbaum et al. 2004). In addition, 
specific MAb productivities of 55 pg/cell/day and 4 g/L yields in non-optimized 
bioreactors have been attained after transferring MAb-SATACs to various industrial 
strains of CHO cells, demonstrating high level SATAC-encoded transgene expression 
(Kennard et al. 2009a). 
  
Isolation and transfer of SATACs 
SATACs are purified to near homogeneity by high-speed flow sorting due to their unique 
nucleotide composition (a predominance of AT base pairs to GC base pairs compared 
with endogenous host cell chromosomes) (deJong et al. 1999), and are the only 
technology that permits the large scale production of purified gene-loaded MACs. 
Isolated SATACs have been microinjected into the pronuclei of murine embryos to 
generate transgenic mice (Blazso et al. 2011; Co et al. 2000) . On the other hand, very 
little success has been made in microinjecting mammalian cells in vitro due to the large 
outer diameter sizes (2.3 – 3.2 μm) of the microinjection needles (Monteith et al. 2004). 
The delivery of transgene-loaded SATACs to primary mammalian cells is a fundamental 
challenge for gene therapy applications. Microcell-mediated chromosome transfer 
(MMCT) has been the most commonly used technique for transferring MACs to various 
cell types. This method is tedious and generally inefficient (10-7 to 10-5) (Doherty and 
Fisher 2003; Fournier and Ruddle 1977; Meaburn et al. 2005; Schor et al., 1975). 
Recently gene-loaded 21ΔqHACs have been transferred to human primary fibroblasts 
(Kakeda et al. 2005) and to human hematopoietic stem cells (HSCs) (Yamada et al. 2006) 
at clinically relevant frequencies of 1.26 x 10-4 and 4.0 x 10-4, respectively. Nevertheless, 
despite these increased transfer efficiencies, during the process of microcell formation the 
host cell generates a heterogeneous population of microcells encapsulating endogenous 
chromosomes as well as MACs. Consequently, this transfer technique increases the 
probability that host chromosomes and chromosomal fragments will be co-transferred 
with MACs to the clinical target cells, which may result in unknown and potentially 
deleterious effects to the patient. It was also demonstrated that a mouse artificial 
chromosome vector developed from a natural mouse chromosome by chromosome 
engineering was more stably maintained in adult tissues and hematopoietic cells in mice 
than HAC vectors. These MACs were stably maintained in human HT1080 cells in vitro 
during long-term culture, in mice at least to the F8 and F4 generations in ICR and 
C57BL/6 backgrounds, respectively, and in hematopoietic cells and tissues derived from 
old mice (Kazuki et al. 2013) . Since SATACs could be purified to near homogeneity, it 
was possible to transfer them to various cell types, including human mesenchymal stem 
cells (MSCs) (Vanderbyl et al. 2004) and HSCs (Vanderbyl et al. 2005) using 
commercially available cationic reagents and dendrimers (de Jong et al. 2001) with high 
transfer efficiencies (10-2-10-4). SATACs loaded with a therapeutic transgene have been 
transferred to murine ESCs by dendrimer-mediated chromosome transfer, establishing 
stem cell clones carrying intact SATACs, which was verified by fluorescent in situ 
hybridization (Katona et al. 2008; Katona, 2011). These murine ESCs were used to treat 
Krabbe disease in the Twitcher mice. The combination of flow cytometry purification 
and cationic reagents/dendrimer mediated delivery of SATACs into embryonic stem and 
iPS cells opens the road for cell therapy based applications. First of all, these cell types 
could be cultured and expanded indefinitely. Once the SATAC was delivered, proper cell 
lines could be selected and analyzed. We keep only those for further experiments, which 
carry an intact SATAC, express the therapeutic genes at the desired level and there is no 
trace of random integration and undesired chromosome fragments in the cells. These 
embryonic stem and iPS cells have high value for cell therapy, because these could be 
differentiated into the desired cell types. The differentiated cell types could be separated 
from undifferentiated ones by FACS. This is achieved by a fluorescent marker gene that 
is only active in the differentiated cell line and expressed from the SATAC. Sorted cells 
are used for direct cell therapy. Adult stem cells are also available for SATAC delivery as 
it was discussed earlier. These stem cells are multipotent and could be differentiated to 
various cell types. Embryonic and adult stem cell banking may decrease the costs of the 
technology. It was speculated that about 100 cell lines might be enough to give 
immunocompetent cells for every patients in a given human population. So, in theory cell 
banking could be done for any particular disorder with the proper therapeutic SATAC 
included. 
 
Stability of SATACs 
In general MAC stability has been assessed in immortalized cell lines, such as human 
HT1080 fibrosarcoma cells, LMTK- and CHO rodent cells . The karyotypes of these cells 
vary greatly in culture, particularly after rounds of MMCT, cationic lipid/dendrimer 
transfections and drug selection, which in turn may not replicate the human primary cell 
environment for the MAC centromere function. The transfer of SATACs into primary 
human MSCs and HSCs demonstrated both autonomous chromosome maintenance and 
stable transgene expression (Vanderbyl et al. 2004; Vanderbyl et al. 2005). Mouse ES 
cell lines carrying therapeutic SATACs maintained high quality karyotypes, preserved 
their pluripotent state (which was verified by the expression of four widely accepted 
pluripotency markers alkaline-phosphatase, Nanog, Sox2 and Oct3/4), and expressed the 
therapeutic transgene (Katona et al. 2008). Under non-selective culture conditions, 98.9 
% of the stem cells retained the therapeutic ACE through more than 100 cell generations. 
When the colonies of these cells were differentiated to embryoid bodies (EBs), 
therapeutic SATAC chromosomes were found in ~99 % of the nuclei of the EBs (Katona 
et al. 2008). These cells were differentiated into cell types of all three germ layers and 
SATACs were present in the nuclei of these cells (Katona et al., unpublished results). 
Transgenic animals have been generated by pronuclear microinjection of purified 
SATACs (Co et al. 2000), and by blastocyst injection of murine ESCs modified with 
SATACs (Katona et al. 2008). Additionally, SATACs have been passed on to more than 
three generations through the mouse germline demonstrating meiotic stability (Co et al. 
2000), providing further evidence that SATAC centromeres function properly in vivo. 
The SATAC transgenic founder mice and their progeny were healthy, robust, and free of 
neoplasms which provided initial evidence that SATACs are safe for in vivo applications 
(Co et al. 2000). 
 
How safe is a MAC? 
MACs are prospectively safer alternatives to viral gene therapy vectors, which have been 
shown to produce insertional oncogenesis (Cavazzana-Calvo et al. 2003; Morillon et al. 
2003), be associated with chromosomal deletions/rearrangements (Miller et al. 2002; 
Miller et al. 2004), induce systemic toxicity (Christ et al. 1997), demonstrate shedding in 
patient semen (Couto 2004), , and cause serious antigenic responses (Evans et al. 2008; 
Raper et al. 2003). These safety issues may be addressed with non-integrating, 
autonomously replicating MACs, thereby providing mitotic stability and consistent 
vector/transgene copy number, as well as eliminating viral deleterious effects. As 
described earlier, SATACs are professedly devoid of gene sequences that could lead to 
indirect or direct dosage effects in cells destined for patient implantation. Moreover, 
transferring flow sorted SATACs by cationic/dendrimer reagents assures that only the 
therapeutic SATAC is delivered to patients, reducing the risk of delivering host 
chromosomes and chromosomal fragments via MMCT. SATACs also carry a suicide 
gene built-in. Presently, it is the thymidine kinase gene from Herpes simplex virus. A 
simple treatment with an orally administered drug (e.g. Aciclovir) can eliminate all the 
SATAC carrying cells from the patient's body. Certain therapeutic procedures, like 
cancer treatment, may even require this therapeutic cell elimination step after the 
treatment was successfully concluded. Recently, HAC vectors were produced with a new 
safeguard system and they can be easily eliminated from cells by inactivation of the HAC 
kinetochore via binding of tTS chromatin modifiers to its centromeric tetO sequences  
(Cardinale et al. 2009; Kononenko et al. 2013; Nakano et al. 2008) . 
 Combined mammalian artificial chromosome stem cell applications 
The applications for stem cell therapy are as diverse as the scope of target diseases, 
therefore, the host stem cell with the most potential would be one with multi-lineage 
capacity, such as embryonic stem cells and adult derived early progenitor cells. Initially 
human embryonic stem cells (hESCs) derived from embryos caused ethical resistance. 
However, this issue seem to have been addressed by the successful establishment of 
permanent ESC lines (Guhr et al. 2006), the isolation of pluripotent spermatogonial stem 
cells from adult testis tissue (Guan et al. 2006) , and the generation of fully pluripotent 
stem cells from cultured human primordial germ cells (Donovan and de Miguel 2003; 
Shamblott et al. 1998), from single blastomere (Klimanskaya et al. 2006), individualized 
ESC cell lines through somatic cell nuclear transplantation (Hochedlinger and Jaenisch 
2006). A novel option for deriving multi-lineage cells was the formation of induced 
pluripotent stem (iPS) cells generated from various human and mouse cell types by 
introducing protein and RNA factors and small molecules under ESC culture conditions 
(Inoue et al. 2014; Takahashi and Yamanaka 2006; Takahashi et al., 2007; Yamanaka 
2012; Yu et al. 2007). Unfortunately, these iPS cells are different from hESCs in many 
respects such as epigenetic status and initial differentiation potential. However, we can 
consider the two cell types as complementary, interdependent biomedical research tools 
(Li et al. 2012; Orkin and Hochedlinger 2011; Papp and Plath 2013; Scott et al. 2011). 
Direct transplantation of ESCs and iPS cells can result in the development of teratomas 
(Evans and Kaufman 1981; Thomson et al. 1998) representing a serious safety issue. 
There is a controversy regarding the direct therapeutic application of MSCs, namely, that 
transplanted MSCs continue to replicate in vivo and preferentially incorporate into tumor 
stroma, constituting a significant fraction of the stromal tissue, possibly supporting tumor 
growth and induce resistance to chemotherapy (Aboody et al. 2006a; Aboody et al. 
2006b; Danks et al. 2007; Houthuijzen et al. 2012; Hung et al. 2005; Karnoub et al. 2007; 
Koh and Kang 2012; Orimo et al. 2005; Roodhart et al. 2011; Studeny et al. 2004; Zhu et 
al. 2006). The risk of tumorigenesis may be overcome with the use of stem cells partially 
differentiated ex vivo, prior to transplantation. ESC differentiation models have 
established the potential to generate large numbers of lineage specific cells for cell 
replacement therapies. Mesoderm-derived lineages, including the hematopoietic lineages 
(Burt et al. 2004; Kondo et al. 2003; Kyba et al. 2002; Nakayama et al. 2000; Park et al. 
2004), vascular (Bautch et al. 1996; Doetschman et al. 1985; Yamashita et al. 2000), and 
cardiac (Hidaka et al. 2003; Kolossov et al. 1998; Min et al. 2002; Min et al. 2003; 
Müller et al. 2000; Yang et al. 2002; Zandstra et al. 2003), are among the easiest to 
generate from ESCs and have been studied in considerable detail. Furthermore, methods 
have been established for selectively expanding multipotential hematopoietic cell 
populations (Kyba et al. 2003; Pinto et al. 1998), neutrophils (Lieber et al. 2004), 
megakaryocytes (Eto et al. 2002), mast cells (Tsai et al. 2000), eosinophils (Hamaguchi-
Tsuru et al. 2004), dendritic cells (Fairchild et al. 2003), and erythroid cells (Carotta et al. 
2004; Chang et al. 2006). Several studies have provided evidence for the generation of 
endoderm-derived cell types including populations that display characteristics of 
pancreatic islets (Colman 2004; D’Amour et al. 2005; D’Amour et al. 2006; Stoffel et al. 
2004), hepatocytes (Hamazaki et al. 2001; Jones et al. 2002; Yamada et al. 2002a), 
thyrocytes (Lin et al. 2003), lung (Ali et al. 2002), and intestinal cells (Yamada et al. 
2002b). Different protocols have also been established to promote neuroectoderm 
differentiation: oligodendrocytes capable of forming myelin sheaths around host neurons 
when transplanted into a myelin-deficient rat model of multiple sclerosis (Brustle et al. 
1997), glial precursors (Brustle et al. 1999), midbrain dopaminergic neurons (Barberi et 
al. 2003; Kim et al. 2002), primitive neural stem cells (Tropepe et al. 2001). In addition 
to the neural lineages, ESCs can also give rise to epithelial cells that will undergo 
differentiation to populations that express markers of keratinocytes (Bagutti et al. 1996).  
ES-cell-derived keratinocytes were able to form structures that resemble embryonic 
mouse skin, indicating that they possess some capacity to generate a functional tissue 
(Coraux et al. 2003). Retinal cells (Osakada et al. 2009) were also produced from human 
ES cells. Exhaustive studies will have to be conducted to determine whether induced ESC 
differentiation generates bona fide functional cells in vivo. The adult derived blastomere-
like and epiblast-like stem cell types (Young et al. 2005) exemplifies prime candidates 
with ES-like differentiation capacity. Multipotent stem cells have been derived from bone 
marrow (Serafini et al. 2007; Young et al. 2005), dental pulp (Atari et al. 2011; Atari et 
al. 2012; Petrovic and Stefanovic 2009), adipose tissue (Fraser et al. 2006), and amniotic 
fluid (De Coppi et al. 2007). In addition, MACs encoding synthetic or natural genetic 
networks may be used to program pluripotent stem cells (natural or MAC-generated iPS 
cells) to follow specific lineage pathways to minimize the potential tumorigenicity issues. 
 
Clinical Applications of MAC-modified stem cells 
Pluripotent or multipotent stem cells carrying SATACs encoding diverse combinations of 
transgenes may be considered for a variety of clinical applications. These SATACs 
expressing complex gene pathways could be converted into “bioreactors” generating 
blood cells (e.g., platelets, red blood cells), immune cells (e.g., artificial antigen 
presenting cells), and pancreatic islet cells. Xenogeneic or allogeneic transplantable 
organs may someday be produced in which SATAC-encoded sequences could “down 
regulate” (by RNA interference technologies) the expression of host stem cell MHC class 
I/II loci and substitute MAC-encoded patient specific loci and appropriate 
transgenes to eliminate the lifetime need for immunosuppressive drugs 
posttransplantation. Recent discoveries that stem/progenitor cells preferentially home to 
tumor sites (Aboody et al. 2006A; Aboody et al. 2006B; Danks et al. 2007; Studeny et al. 
2004) offer the possibility for tumor therapy with artificial chromosomes armed with an 
arsenal of transgenes, including a drug-prodrug suicide system, cytokines (e.g., 
interferon-β) and antibodies. 
 
Cell therapy 
At present, there is no ongoing clinical trial with artificial chromosomes. However, 
preliminary results of preclinical experiments (Adriaansen et al. 2006; Auriche et al. 
2001; Auriche et al. 2002; Carl 2004; Kakeda et al. 2005; Katona et al. 2008; Kawahara 
et al. 2007) have made a case for the feasibility of MAC-based ex vivo cell therapies 
where constitutive or overexpression of therapeutic gene(s) is acceptable or required. The 
successful transfer of MACs to MSCs (Bunnell et al. 2005; Ren et al. 2005; Vanderbyl et 
al. 2004), HSCs (Doherty and Fisher 2003; Vanderbyl et al. 2005) and ESCs (Katona et 
al. 2008), and the subsequent MAC transgene expression in differentiated cell types have 
opened a wide range of indications, including, hematological diseases, immunodeficiency 
diseases, lysosomal storage diseases and cancer (Bunnell et al. 2005; Carl 2004) . The 
non-exhaustive list above indicates the broadness of diseases and disorders which could 
be targeted with specific strategies and protocols (e.g., central nervous system, see review 
(Goldman 2005)). In most of the cases, generation of stem cell derived therapeutic 
lineages require multiple transgenes, including a combined positive/negative selection 
and/or marker system (Billon et al. 2002; Klug et al. 1996; Li et al. 1998), in order to 
eliminate non-differentiated stem cells. Platform ACEs by means of multiple acceptor 
sites have the capacity to harbor such complex genetic accessories. Recently, a novel 
method was described to load multiple genes onto the Platform ACEs by using only two 
selectable marker genes (Tóth et al. 2014). These markers may be removed from the 
ACEs before therapeutic application. This novel technology could revolutionize gene 
therapeutic protocols targeting the treatment of complex disorders and cancers. It could 
also speed up cell therapy by allowing researchers to engineer a chromosome with a 
predetermined set of genetic factors to differentiate adult stem cells, embryonic stem cells 
and induced pluripotent stem (iPS) cells into cell types of therapeutic value. Most 
importantly these stem cells can potentially avoid immune response, because they may 
originate from the patient's own tissues. It is also a suitable tool for the investigation of 
complex biochemical pathways in basic science by producing a SATAC with several 
genes from a signal transduction pathway of interest. 
 
Tracking and eliminating SATACs in patients 
SATACs may be engineered to express an artificial magnetic resonance gene encoding 
lysine rich-protein (Gilad et al. 2007) or human protamine-1 (Bar-Shir et al. 2014). The 
location of the SATACs and any in vivo derived differentiated tissue may be detected by 
magnetic resonance imaging (MRI), providing a powerful non-invasive approach to 
monitor therapeutic cell fate. Micro-PET analysis also can be used to follow cell fate in 
vivo (Gyöngyösi et al. 2008). Finally, these therapies could be terminated by loading 
SATACs with the thymidine-kinase gene of Herpes simplex virus. An orally 
administered drug (e.g. Aciclovir) treatment may eliminate all the cells that are carrying 
the SATAC. Therefore, the large payload capacity of SATACs will ultimately enable 
reprogramming of pluripotent stem cells to specific lineages, therapeutic transgene 
expression, surveillance of tissue engraftment, and the precise termination of therapy. 
Closing remarks 
While the imperfection of viral vectors still hamper the long awaited breakthrough in 
gene therapy, mammalian artificial chromosomes are being developed as potentially safer 
genetic vectors for the therapeutic modification of human stem cells. HACs and SATACs 
have made the greatest progress in demonstrating efficient gene loading and the 
subsequent transfer and stable transgene expression in embryonic and adult stem cells.  
Crucially these genetic vectors were maintained as autonomous chromosomes that 
facilitated transgene expression during stem cell differentiation and animal development. 
These proof-of-concept studies are the first steps towards exploiting their potential for 
safer and coordinated control of stem cell differentiation and therapeutic transgene 
expression. To bring MAC-based stem cell therapies to the clinic, further advances in 
MAC technology should be made, including the demonstration of inducible promoter 
systems required for the fine-tuned control of therapeutic transgene expression and the 
potential activation of suicide transgenes, like Herplex simplex virus thymidine-kinase, 
for managed gene therapy termination; the loading and expression of genetic pathways 
that control the lineage specific differentiation of pluripotent stem cells; and the 
establishment of MAC platform stem cell lines demonstrating controlled differentiation 
and long-term transgene expression and subsequent cell banking for better and faster 
therapies. MAC-modified stem cells have great potential to address a wide spectrum of 
diseases. Amongst these the most prominent are the therapies for genetic disorders 
without viable treatments where the constitutive overexpression of single or multiple 
transgenes are necessary and cancer therapies. The success of these trials will enable the 
engineering of genetic pathways and networks, which in turn will facilitate greater 
control of therapeutic transgene expression, tracking transplant fate, and transplant safety, 
thereby realizing the potential of modifying stem cells with mammalian artificial 
chromosomes for the treatment of human diseases. 
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Figure 1.  A step by step overview of SATAC formation. A The drawing shows the 
major components of an acrocentric chromosome that carries rDNA genes on the 
short arm. B A foreign DNA including the gene(s) of interest is integrated into the 
rDNA region of the acrocentric chromosome. Homologous rDNA sequences are 
either co-transfected or co-constructed with the foreign DNA to facilitate higher 
probability of specific integration. C Foreign DNA integration induces large 
scale, replication-dependend amplification in the short arm of these acrocentric 
chromosomes. This type of amplification process occurs in mammals and even in 
humans in nature with a low frequency. D A duplication of a functional 
centromere can take place in the amplification process. E A breakage occurs in 
the region between the two centromeres when cells divide. F An independent 
chromosome, the de novo SATAC is formed. This SATAC has all the necessary 
components for proper maintenance, replication and segregation in cell cycle and 
cell division. The SATAC also contains and expresses the integrated gene(s) of 
interest. 
